SUPARTZ Versus Placebo in Osteoarthritis of the Shoulder
NCT ID: NCT00479687
Last Updated: 2021-04-27
Study Results
Outcome measurements, participant flow, baseline characteristics, and adverse events have been published for this study.
View full resultsBasic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
NA
300 participants
INTERVENTIONAL
2007-05-31
2009-10-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Non-Inferiority Study Comparing 3 Weekly Injections of SUPARTZ® vs 3 Weekly Injections of Euflexxa® for Knee OA
NCT02110238
HUPS: Hyalgan Use in Painful Shoulder
NCT00377624
Platelet-rich Plasma vs. Hyaluronic Acid for Glenohumeral Osteoarthritis
NCT02984228
ZILRETTA in Subjects With Shoulder Osteoarthritis
NCT06269705
A Study Evaluating the Safety and Efficacy of SM04690 for the Treatment of Moderately to Severely Symptomatic Knee Osteoarthritis
NCT03122860
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
TREATMENT
QUADRUPLE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Supartz
SUPARTZ® 3 injections over 2 weeks
SUPARTZ®
Three Supartz injections over 2 weeks into the glenohumeral joint space.
Phosphate Buffered Saline
Phosphate Buffered Saline 3 injections over 2 weeks
Phosphate Buffered Saline
Three phosphate buffered saline injections over 2 weeks into the glenohumeral joint space.
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
SUPARTZ®
Three Supartz injections over 2 weeks into the glenohumeral joint space.
Phosphate Buffered Saline
Three phosphate buffered saline injections over 2 weeks into the glenohumeral joint space.
Other Intervention Names
Discover alternative or legacy names that may be used to describe the listed interventions across different sources.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Limitation of shoulder motion in at least one direction
* Retained active range of motion of at least 30% in all directions
Exclusion Criteria
* Frozen shoulder
* Female who is pregnant or lactating
35 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Bioventus LLC
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Scott Sledge, MD
Role: PRINCIPAL_INVESTIGATOR
Northeast Orthopedics - Unlimited Research
Charles Birbara, MD
Role: PRINCIPAL_INVESTIGATOR
Clinical Pharmacology Study Group
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
SHO-0106
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.